Patients who received co-prescription of calcium channel blockers, known CYP3A4 inhibitors (i.e., amlodipine, diltiazem, felodipine, nicardipine, nifedipine, and verapamil), and CYP3A4-metabolized statins (i.e., lovastatin, simvastatin, and atorvastatin) had significantly higher risk of acute kidney injury, hyperkalemia, acute myocardial infarction, and acute ischemic stroke than those who received non-CYP3A4-metabolized statins (i.e., fluvastatin, rosuvastatin, and pitavastatin) [150]. Here, CYP3A4 is linked to myocardial infarction.